Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy.

Trial Profile

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jan 2014

At a glance

  • Drugs Irinotecan (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colon cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms PARAGON-Louisville
  • Most Recent Events

    • 18 Jan 2014 Primary endpoint 'Objective-clinical-response-rate' has been met.
    • 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.
    • 15 Nov 2011 Additional trial location (Argentina) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top